GlassScriptPhysician profile
Vy Nguyen
NPI 1184604944
$4,372.91
in general payments reported to CMS, 2019-2025
20 companies · $804 in 2025
The $804 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $330 · 2021: $276 · 2022: $415 · 2023: $367 · 2024: $409 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.26 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $904.76 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $480.93 | 2023-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $433.40 | 2019-2024 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.18 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $226.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $223.81 | 2019-2024 | Capvaxive |
| Amarin Pharma, INC. | $210.00 | 2019 | |
| Redhill Biopharma INC. | $209.37 | 2022-2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.53 | 2019 | |
| Astellas Pharma US INC | $191.65 | 2019-2024 | Veozah |
| Allergan, INC. | $139.08 | 2019 | |
| Pfizer INC. | $133.43 | 2019 | |
| Abbvie INC. | $125.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $119.92 | 2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $116.55 | 2019 | |
| Gilead Sciences, INC. | $113.64 | 2019 | |
| Ethicon US, LLC | $106.07 | 2025 | Echelon; Endopath |
| Glaxosmithkline, LLC. | $15.17 | 2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vy Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.